MXCT vs SRPT · rev $38.6M vs rev $1.90B
MaxCyte Inc (MXCT) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
MXCT currently screens at market cap $124.3M. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the MXCT and SRPT stock pages for the full models.
Not investment advice.